Systemic coagulation network

The systemic coagulation network is a complex physiological system of plasma proteins, platelets, and endothelial cells that work in concert to maintain hemostasis and prevent blood loss following vascular injury (StatPearls, NBK507795). It is traditionally divided into the intrinsic, extrinsic, and common pathways, which culminate in the generation of thrombin and the subsequent conversion of soluble fibrinogen into an insoluble fibrin mesh (Wikipedia, Coagulation). This network is tightly regulated by natural anticoagulants such as protein C, protein S, and antithrombin to prevent excessive clot formation (NIH, MedlinePlus). Dysregulation of this network can lead to life-threatening conditions, including pathological thrombosis, stroke, or hemorrhagic disorders like Hemophilia (PubMed, PMID: 28631411). Pharmacological intervention typically targets specific enzymatic components of the cascade, such as Factor Xa or Thrombin, to reduce the risk of venous thromboembolism and systemic embolism (Journal of Thrombosis and Haemostasis). Modern anticoagulants, including direct oral anticoagulants (DOACs), offer more predictable pharmacokinetics and fewer dietary restrictions compared to traditional vitamin K antagonists like warfarin (FDA, Drug Safety Communications). Monitoring the efficacy of these interventions often involves laboratory assays like the Prothrombin Time (PT) or Activated Partial Thromboplastin Time (aPTT) (Mayo Clinic). Understanding the network's feedback loops and its cross-talk with inflammatory pathways is crucial for developing safer and more effective antithrombotic therapies that minimize bleeding risks.

Other names

Coagulation cascadeHemostatic systemBlood clotting pathwayClotting cascadeCoagulation system

Drugs targeting the systemic coagulation network act by inhibiting specific serine proteases such as Factor Xa or Thrombin, antagonizing vitamin K-dependent carboxylation of clotting factors, or accelerating the activity of natural anticoagulants like antithrombin III to prevent the formation of fibrin clots.